Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Next Science Ltd ( (AU:NXS) ) has shared an announcement.
Next Science Limited is set to release its fourth quarter financial results for the fiscal year 2024 on January 23, 2025. Following the announcement, the CEO and CFO will host an investor webinar to discuss the results and engage with the investment community. This upcoming event signifies the company’s commitment to transparency and stakeholder engagement, potentially impacting its market position and investor relations.
More about Next Science Ltd
Next Science is a medical technology company based in Sydney, Australia, with a research and development center in Florida, USA. Founded in 2012, it focuses on the development and commercialization of its proprietary XBIO™ technology, aimed at reducing biofilm-based infections in human health. XBIO™ is a unique, non-toxic technology that effectively eradicates biofilm-based and free-floating bacteria, and the company holds complete patent rights to this technology.
YTD Price Performance: 12.86%
Average Trading Volume: 20,438
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $24.42M
See more data about NXS stock on TipRanks’ Stock Analysis page.
